Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.

The Muttenz-based biotech startup proposes an alternative to culture-based antibiograms, the current gold standard in antibiotic susceptibility testing. The EPFL spin-off offers a diagnostic device, the rapid AST method, which is based on the detection of movement caused by living bacterial cells. The new method reduces the time taken to get a result from days to minutes, shows which specific antibiotic is effective against the bacteria, and significantly improves the chances of patients’ survival.

Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.